Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Niaspan Prescribers for Raising HDL(?)

Council Members in this Study Group: 142

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Howard Weintraub, MD
Clinical Director
NYU Medical Center

Howard Weintraub, MD, FACC, is the Clinical Director of Center for the Prevention of Cardiovascular Disease at NYU Medical Center. He has been a consultant for several organizations and has been a Cardiologist for the National Football League. Dr. Weintraub has written textbook chapters on evaluation...

Harold Bays, MD, FACP, President and Medical Director, L-MARC Research CenterHarold Bays, MD, FACP
President and Medical Director
L-MARC Research Center

Harold Bays, MD, FACE, FACP, is Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center (L-MARC), a metabolic clinical research facility that has conducted over 400 phase I-IV clinical trials, including studies of all marketed lipid-altering drug treatments, as well...

Hossein Ardehali, MD, PhD, Assistant Professor, Feinberg School of Medicine, Northwestern UniversityHossein Ardehali, MD, PhD
Assistant Professor
Feinberg School of Medicine, Northwestern University

Hossein Ardehali, MD, PhD, is an Assistant Professor of Medicine at Feinberg Cardiovascular Institute in Illinois. His specialties include lipid metabolism, preventive cardiology, electrophysiology and heart failure. Dr. Ardehali's basic science research interest is in the areas of reperfusion injury...

Joshua Feuer, MD
Owner
Joshua M. Feuer, MD

Joshua Feuer, MD, FACC, is a board certified Cardiologist in private practice in Santa Barbara, California. He also serves as a Consulting Cardiologist at Santa Barbara Cottage Hospital. Dr. Feuer specializes in aggressive preventive cardiology and cardiovascular risk assessment, and reduction. He has...

Dan Streja, MD
Clinical Professor of Medicine
University of California, Los Angeles

Dan Streja, MD, is a Clinical Professor of Medicine at the University of California, Los Angeles. He is Co-Director of the Lipid Clinic, the Cardiovascular Prevention Clinic and Diabetes Clinic, and the Divisions of Cardiology and Endocrinology at VA Medical Center of West Los Angeles. Dr. Streja has...

Michael Davidson, MD, FACC, Director, Preventive Cardiology, The University of ChicagoMichael Davidson, MD, FACC
Director, Preventive Cardiology
The University of Chicago

Michael Davidson, MD, FACC, is the Executive Medical Director at Radiant Research Inc. and Director of Preventive Cardiology and Atherosclerosis Research and Clinical Professor of Medicine at the University of Chicago. In addition, he is Founder, President, and Chief Executive Officer of the Chicago...

Bernard Chaitman, MD, Professor and Director, SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINEBernard Chaitman, MD
Professor and Director
SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE

Bernard Chaitman, MD, is a Professor of Internal Medicine and Director of Cardiovascular Research at St. Louis University School of Medicine, Missouri. He is also the Director of Core ECG Laboratory. Dr. Chaitman has research interests in anti-anginal drug therapies including Ranolazine, Nicorandil,...

Samuel Butman, MD, Interventional Cardiologist, Verde Valley Heart LLCSamuel Butman, MD
Interventional Cardiologist
Verde Valley Heart LLC

Samuel Butman, MD, is an Interventional Cardiologist at Verde Valley Medical Center. Dr. Butman is also a Clinical Associate Professor of Medicine at University Medical Center in Tucson, Arizona. He has also served as the Director of Cardiology Interventional Fellows Program and Director of Cardiac...

View all Leading Experts in this Study Group

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Byetta Preventing Mortality? Even IF True, Wrong Formulation? | 08-11-2008
Author: GLG Expert Contributor

The recent finding that Byetta therapy decreased mortality in the ACCORD study needs to be replicated in studies designed to address that point.  Even if it is replicated and statistically significant, it probably will not be true for the widely anticipated once weekly extended formulation...

Statin therapy for children | 08-06-2008
Author: GLG Expert Contributor

The  potential market for treatment of lipids(cholesterol)continues to grow. Recent recommendations regarding potential for treatment of children as young as 8 are controversial, primarily because of the lack of data to demonstrate efficacy in terms of "hard" endpoints(i.e. mortality/MI)vs. morbidity...

Exenatide may provide practical and cost convenient efficacy in tratment of Metabolic Syndrome patients | 06-23-2008
Author: GLG Expert Contributor

More than 50% of patients have the 3 ccomponents to qualify for diagnosis of Metabolic Syndrome.Twwo of the components,Diabetes and Obesity are present in 20-25% of them and are difficult to control.Exenatide seems to provide that benefit.

Race to Market, with Competition Hot on Heels | 06-19-2008
Author: GLG Expert Contributor

As exciting as the DURATION I study results have been, Roche's GLP-1 agonist is also looking good in earlier phase trials, and there are MANY competitors in this GLP-1 realm, as well as the gliptins (oral, with similar efficacy on glucose and A1c but without the dramatic weight loss), chomping at the...

AGI-1067 May Address More than the Blood Sugar | 05-30-2008
Author: GLG Expert Contributor

This compound may have additiional benefit in type 2 diabetic patients, especially those with the cardiometabolic syndrome. 

View All GLG News by members of this Study Group

Most Common Company Types:

  • Office Based Private Practice or Clinic
  • Academic Medical Center/Hospital or Clinic
  • Non-Academic Community Hospital or Clinic
  • Government/Military Hospital or Clinic

Most Common Job Types:

  • Physician - Attending Physician
  • Owner
  • Physician - Director
  • Partner

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-09-05T05:45:18.073